EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population
- 41 Downloads
Epidermal growth factor (EGF) and its receptor (EGFR) play an important role in lung carcinogenesis. A functional single nucleotide polymorphism (SNP) in EGF promoter region (EGF+61 A>G—rs4444903) has been associated with cancer susceptibility. Yet, in lung cancer, the EGF+61 A>G role is unclear. The aim of this study was to evaluate the risk of lung cancer associated with EGF+61 A>G SNP in the Brazilian population. For that, 669 lung cancer patients and 1104 controls were analyzed. EGF+61 A>G genotype was assessed by PCR-RFLP and TaqMan genotyping assay. Both patients and controls were in Hardy–Weinberg equilibrium. As expected, uni- and multivariate analyses showed that tobacco consumption and age were significant risk factors for lung cancer. The genotype frequencies in lung cancer patients were 27.3% of AA, 47.4% of AG and 25.3% of GG, and for controls were 25.3% of AA, 51.6% of AG and 23.1% of GG. The allele frequencies were 51.1% of A and 48.9% of G for both cases and controls. No significant differences for the three genotypes (AA, AG and GG—codominant model) were observed between cases and controls. We then grouped AG and GG (recessive model) genotypes, as well as AA and AG (dominant model), and again, no significant differences were also found. This is the largest study to explore EGF+61 A>G polymorphism association with lung cancer risk and suggests that this SNP is not a risk factor for lung cancer in the Brazilian population.
KeywordsLung cancer SNP Risk factor EGF+61 A>G polymorphism
The authors would like to thank Barretos Cancer Hospital Research Support Department (NAP) for sample collection and Barretos Cancer Hospital Biobank for sample processing.
This study was partially supported by FINEP - CT-INFRA (02/2010) and Barretos Cancer Hospital Research Fund (PAIP).
Compliance with ethical standards
Conflict of interest
None of the authors have any financial or non-financial conflict of interests.
All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration or its later amendments or comparable ethical standards. The study was approved by Barretos Cancer Hospital Ethics Committee (#596/2012).
Signed informed consents were obtained from all control individuals and cases included in the study that provided blood samples. From the FFPE cases, due to the retrospective nature of the study, the Barretos Cancer Hospital Ethics Committee exempted informed consent.
- 2.INCA (2018) Estimativas 2018. In. INCA. http://www.inca.gov.br/estimativa/2018/. Accessed 04 Oct 2018
- 3.DATASUS (2018) Sistema de informações sobre mortalidade. In: Ministério da Saúde. http://www.datasus.gov.br. Accessed 14 Jan 2019
- 4.Akhtar N, Bansal JG (2017) Risk factors of Lung Cancer in nonsmoker. Curr Probl Cancer. https://doi.org/10.1016/j.currproblcancer.2017.07.002 Google Scholar
- 8.TCGA The Cancer Genome Atlas. https://tcga-data.nci.nih.gov/docs/publications/tcga/?. Accessed 28 Sept 2018
- 9.ICGC International Cancer Genome Consortium. https://dcc.icgc.org/
- 10.Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ (2017) Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 7(6):596–609. https://doi.org/10.1158/2159-8290.CD-16-1337 CrossRefGoogle Scholar
- 12.Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359(9304):397–401. https://doi.org/10.1016/S0140-6736(02)07600-6 CrossRefGoogle Scholar
- 13.Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM, Reis RM (2007) Association between functional EGF + 61 polymorphism and glioma risk. Clin Cancer Res Off J Am Assoc Cancer Res 13(9):2621–2626. https://doi.org/10.1158/1078-0432.CCR-06-2606 CrossRefGoogle Scholar
- 17.Lim YJ, Kim JW, Song JY, Hong MS, Jin SY, Yoon SH, Park HJ, Choe BK, Lee JJ, Yim SV, Hong SI, Baik HH, Ha E, Park YH (2005) Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett 374(3):157–160. https://doi.org/10.1016/j.neulet.2004.10.055 CrossRefGoogle Scholar
- 19.de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J, Oliveira P, Hespanhol V, Reis RM (2012) Association between EGF + 61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study. Tumour Biol 33(5):1341–1348. https://doi.org/10.1007/s13277-012-0382-7 CrossRefGoogle Scholar
- 23.Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, Pina F, Calais-da-Silva F, Medeiros R (2008) Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res 14(11):3367–3371. https://doi.org/10.1158/1078-0432.CCR-07-5119 CrossRefGoogle Scholar
- 29.Elez-Burnjakovic N, Ugrin M, Obradovic J, Miletic N, Racic M, Kulic M, Pavlovic S, Jurisic V (2018) Distribution of EGFR SNPs - 191C/A and 181946G/A in patients with lung cancer depending on smoking status in the Republic of Srpska, Bosnia and Herzegovina. J BUON Off J Balk Union Oncol 23(2):384–390Google Scholar